



Amarin Corporation plc
 Investor Relations Department
 2 Pembroke House, Upper
 Pembroke
 Street 28-32
 Dublin 2
 Ireland

[Visit IR website](#)
[Sign-up for Email alerts](#)

| NASDAQ: AMRN | |
|---------------|-----------------------------|
| Last Trade: | 3.21 |
| Trade Time: | 10:36 AM ET May 21, 2018 |
| Change: | -0.06 (-1.835%) |
| Day Range | 3.21 - 3.30 |
| 52-Week Range | 2.66 - 4.60 |
| Volume | 232,057 |

Stock information is provided by eSignal,
 stock charts provided by EDGAR Online.
 Stock data is delayed approximately 20
 minutes.

Company Profile

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- May 2, 2018
[Amarin Reports First Quarter 2018 Financial Results and Provides Update on Operations](#)
- Apr 26, 2018
[Amarin To Report First Quarter 2018 Results and Host Conference Call On May 2, 2018](#)
- Apr 23, 2018
[Amarin Announces Promotion of Aaron Berg to Position of Chief Commercial Officer](#)
- Apr 12, 2018
[Amarin Sponsors Three Scientific Presentations Scheduled for National Lipid Association Scientific Sessions](#)
- Apr 12, 2018
[Vascepa® \(Icosapent Ethyl\) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin-Treated Patients with Reduced Kidney Function and Persistent High Triglycerides](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- Feb 27, 2018
[Annual Report \(10-K\)](#)
- Apr 20, 2018
[Proxy Statement \(DEF 14A\)](#)
- May 2, 2018
[Quarterly Report \(10-Q\)](#)
- Nov 1, 2017
[Quarterly Report \(10-Q\)](#)
- Aug 2, 2017
[Quarterly Report \(10-Q\)](#)